- Trials with a EudraCT protocol (175)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
175 result(s) found for: Perfusion CT.
Displaying page 8 of 9.
EudraCT Number: 2018-001494-24 | Sponsor Protocol Number: AK2015-10 | Start Date*: 2018-06-26 | |||||||||||
Sponsor Name:Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET | |||||||||||||
Full Title: In vivo molecular imaging of angiogenesis after VEGF-D gene therapy | |||||||||||||
Medical condition: Ischemic heart disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005075-91 | Sponsor Protocol Number: STRATIFY-1 | Start Date*: 2018-08-30 | |||||||||||
Sponsor Name:Copenhagen University Hospital Rigshospitalet | |||||||||||||
Full Title: LOW DOSE THROMBOLYSIS, ULTRASOUND ASSISTED THROMBOLYSIS OR HEPARIN FOR INTERMEDIATE HIGH RISK PULMONARY EMBOLISM | |||||||||||||
Medical condition: Acute Pulmonary Embolism, intermediate high risk (visible impact on right ventricular structure and function, and biochemical markers og myocardial damage according to the European Society of Cardi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001785-26 | Sponsor Protocol Number: 14-505 | Start Date*: 2016-02-15 | |||||||||||
Sponsor Name:Portola Pharmaceuticals, Inc. | |||||||||||||
Full Title: Prospective, Open-label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor who Have Acute Major Bleeding (ANNEXA-4). | |||||||||||||
Medical condition: Uncontrolled bleeding in patients who have taken either a direct factor Xa inhibitor (novel oral anticoagulants) or an indirect factor Xa inhibitor (low molecular weight heparins). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) GB (Completed) BE (Completed) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002631-86 | Sponsor Protocol Number: 1160.46 | Start Date*: 2008-10-23 | ||||||||||||||||
Sponsor Name:Boehringer Ingelheim Austia Gm.b.H | ||||||||||||||||||
Full Title: A phase III, randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute sy... | ||||||||||||||||||
Medical condition: Acute symptomatic VTE VTE is defined as the composite incidence of Deep Vein Thrombosis of the leg (including the inferior caval vein) and Pulmonary Embolism. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) SK (Completed) ES (Completed) GB (Completed) NL (Completed) DK (Completed) CZ (Completed) SE (Completed) HU (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-006192-13 | Sponsor Protocol Number: C200-006 | Start Date*: 2006-06-22 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals US, Inc. | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ADDITION OF INHALED ILOPROST IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) RECEIVING ORAL SI... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) is a condition that is characterized by increased pulmonary arterial pressure and vascular resistance that can lead to right ventricular failure and death. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) PT (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005885-30 | Sponsor Protocol Number: B1321001 | Start Date*: 2010-01-12 | |||||||||||
Sponsor Name:Pfizer Ltd | |||||||||||||
Full Title: A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, SAFETY AND EFFICACY STUDY OF SITAXSENTAN SODIUM IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION | |||||||||||||
Medical condition: Pulmonary arterial hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000728-41 | Sponsor Protocol Number: 06/02-29 jan'07 | Start Date*: 2008-09-12 | ||||||||||||||||
Sponsor Name:Maastro clinic | ||||||||||||||||||
Full Title: A phase I/II trial testing nelfinavir, an inhibitor of Akt signaling, in combination with preoperative chemoradiotherapy in patients with locally advanced rectal cancer | ||||||||||||||||||
Medical condition: A phase I/II trial testing nelfinavir, an inhibitor of Akt signaling, in combination with preoperative chemoradiotherapy with locally advanced rectal cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000307-32 | Sponsor Protocol Number: 20110264 | Start Date*: 2014-11-18 |
Sponsor Name:Amgen Inc. | ||
Full Title: A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV Me... | ||
Medical condition: Unresected, Stage IIIB-IV Melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-005144-84 | Sponsor Protocol Number: ML20383 | Start Date*: 2007-02-14 | |||||||||||
Sponsor Name:Roche SAS | |||||||||||||
Full Title: Essai de phase II évaluant l’efficacité et la tolérance de bevacizumab associé à une chimiothérapie dans le traitement de patients atteints de tumeurs endocrines digestives bien différenciées, prog... | |||||||||||||
Medical condition: Tumeurs endocrines digestives et duodéno-pancréatiques | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004968-56 | Sponsor Protocol Number: OCTO_063 | Start Date*: 2015-11-20 | |||||||||||
Sponsor Name:University of Oxford Clinical Trials & Research Governance | |||||||||||||
Full Title: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/-nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer | |||||||||||||
Medical condition: Locally advanced non-metastatic pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003889-39 | Sponsor Protocol Number: NALPAC | Start Date*: 2021-10-11 |
Sponsor Name:Belgian Group of Digestive Oncology (BGDO) | ||
Full Title: A Non-Comparative Randomized Phase 2 Study, Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Progressive After Gemcitabine-Abra... | ||
Medical condition: Pancreatic ductal adenocarcinoma (PDAC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006638-38 | Sponsor Protocol Number: 2021/3282 | Start Date*: 2022-05-18 |
Sponsor Name:GUSTAVE ROUSSY | ||
Full Title: A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors - VAPOR (GETUG T06) | ||
Medical condition: Non-seminomatous germ-cell tumors (including testis, retroperitoneal and mediastinal primaries) with a disseminated disease (clinical stages II or III according to AJCC 8th edition) and classified ... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002800-16 | Sponsor Protocol Number: C3591024 | Start Date*: 2019-12-10 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME AND AVIBACTAM IN NEONATES AND INFANT... | |||||||||||||
Medical condition: Infections with suspected or confirmed Gram-negative pathogens | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Completed) EE (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000050-32 | Sponsor Protocol Number: GE012-097 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||
Sponsor Name:GE Healthcare Ltd. and its affiliates | |||||||||||||||||||||||
Full Title: A phase 4 randomized, double-blind study comparing patient comfort and safety between iodixanol 320 mg I/ml and iopamidol 370 mg I/ml in patients undergoing contrast-enhanced computed tomographic (... | |||||||||||||||||||||||
Medical condition: Patients undergoing CECT imaging of the abdomen/pelvis as part of their routine medical care. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-005684-32 | Sponsor Protocol Number: | Start Date*: 2015-12-30 | |||||||||||
Sponsor Name:The Royal Marsden NHS Foundation Trust | |||||||||||||
Full Title: [18F] DIHYDRO-TESTOSTERONE PET IMAGING IN PATIENTS WITH PROGRESSIVE PROSTATE CANCER | |||||||||||||
Medical condition: Progressive Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000438-79 | Sponsor Protocol Number: CCD-05993AA1-16 | Start Date*: 2017-09-11 | |||||||||||
Sponsor Name:Chiesi Farmaceutici S.p.A. | |||||||||||||
Full Title: Open label, prospective, exploratory study to investigate the effect of inhaled CHF5993 pMDI on central and peripheral airway dimensions in COPD patients by Functional Respiratory Imaging | |||||||||||||
Medical condition: COPD | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001778-32 | Sponsor Protocol Number: U1111-1149-7801 | Start Date*: 2014-08-12 | |||||||||||||||||||||
Sponsor Name:Bo Feldt-Rasmussen | |||||||||||||||||||||||
Full Title: Glycaemic and cardiovascular efficacy of liraglutide in prediabetic patients with end-stage renal disease | |||||||||||||||||||||||
Medical condition: Prediabetes and dialysis dependent end-stage renal disease | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000166-37 | Sponsor Protocol Number: AIR001-CS05 | Start Date*: 2013-01-22 |
Sponsor Name:Aires Pharmaceuticals Inc | ||
Full Title: A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects with WHO Group 1 Pulmonary Arterial Hypertension | ||
Medical condition: Pulmonary Arterial Hypertension | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-003093-27 | Sponsor Protocol Number: GB002-1101 | Start Date*: 2019-08-16 | |||||||||||
Sponsor Name:GB002, Inc. | |||||||||||||
Full Title: A Phase 1b, Randomized, Subject- and Investigator-Blinded, Placebo-Controlled, Multi-Center Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Biomarkers of Inhaled GB00... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000183-29 | Sponsor Protocol Number: REVISION | Start Date*: 2022-03-09 | |||||||||||
Sponsor Name:Eberhard-Karls University Tübingen, Med. Fac. rep. by University Hospital and its Commercial Director | |||||||||||||
Full Title: Early Reperfusion Therapy with Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion (REVISION) - A double-blind randomized placebo-controlled phase III proof-of-co... | |||||||||||||
Medical condition: Acute non-arteritic central retinal artery occlusion (CRAO) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
